These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6571338)

  • 1. Kinetics of cefsulodin in patients with renal impairment.
    Gibson TP; Granneman GR; Kallal JE; Sennello LT
    Rev Infect Dis; 1984; 6 Suppl 3():S689-97. PubMed ID: 6571338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefsulodin kinetics in renal impairment.
    Gibson TP; Granneman GR; Kallal JE; Sennello LT
    Clin Pharmacol Ther; 1982 May; 31(5):602-8. PubMed ID: 7075110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cefotiam and cefsulodin after simultaneous administration to patients with impaired renal function.
    Lecaillon JB; Rouan MC; Binswanger U; Guibert J; Schoeller JP
    Antimicrob Agents Chemother; 1984 Sep; 26(3):368-72. PubMed ID: 6095754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefsulodin pharmacokinetics in patients with various degrees of renal function.
    Matzke GR; Keane WF
    Antimicrob Agents Chemother; 1983 Mar; 23(3):369-73. PubMed ID: 6847169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single intravenous dose kinetics accumulation of atenolol in patients with impaired renal function and on hemodialysis.
    Kirch W; Schäfer M; Braun M
    Arch Toxicol Suppl; 1980; 4():366-9. PubMed ID: 6933939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of impaired renal function, hemodialysis, and peritoneal dialysis on the pharmacokinetics of mezlocillin.
    Kampf D; Schurig R; Weihermüller K; Förster D
    Antimicrob Agents Chemother; 1980 Jul; 18(1):81-7. PubMed ID: 6448024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
    Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
    Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
    Kirch W; Köhler H; Berggren G; Braun W
    Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefonicid kinetics in subjects with normal and impaired renal function.
    Blair AD; Maxwell BM; Forland SC; Jacob L; Cutler RE
    Clin Pharmacol Ther; 1984 Jun; 35(6):798-803. PubMed ID: 6734031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function.
    Kampf D; Borner K; Möller M; Kessel M
    Clin Pharmacol Ther; 1984 Feb; 35(2):214-20. PubMed ID: 6319069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of renal impairment and hemodialysis on lorazepam kinetics.
    Morrison G; Chiang ST; Koepke HH; Walker BR
    Clin Pharmacol Ther; 1984 May; 35(5):646-52. PubMed ID: 6713774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K
    Antimicrob Agents Chemother; 1986 Dec; 30(6):901-5. PubMed ID: 3468882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cefonicid in uraemic patients.
    Fillastre JP; Fourtillan JB; Leroy A; Ramis N; Lefevre MA; Reumont G; Humbert G
    J Antimicrob Chemother; 1986 Aug; 18(2):203-11. PubMed ID: 3759731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis.
    Hedman A; Alván G; Strandvik B; Arvidsson A
    Clin Pharmacokinet; 1990 Feb; 18(2):168-75. PubMed ID: 2180614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.
    Christensson BA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Oqvist B; Norrby SR
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1532-7. PubMed ID: 1510451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of temocillin (BRL 17421) in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Fillastre JP; Borsa F; Godin M
    J Antimicrob Chemother; 1983 Jul; 12(1):47-58. PubMed ID: 6619046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefamandole pharmacokinetics and dosage adjustments in relation to renal function.
    Brogard JM; Kopferschmitt J; Spach MO; Grudet O; Lavillaureix J
    J Clin Pharmacol; 1979 Jul; 19(7):366-77. PubMed ID: 479381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal disease, age, and oxazepam kinetics.
    Murray TG; Chiang ST; Koepke HH; Walker BR
    Clin Pharmacol Ther; 1981 Dec; 30(6):805-9. PubMed ID: 7307429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of renal function on the elimination kinetics of sulbenicillin in man.
    Montanari A; Borghi L; Canali M; Coruzzi P; Novarini A; Borghetti A
    Int J Clin Pharmacol Ther Toxicol; 1980; 18(5):225-8. PubMed ID: 7390672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of multiple-dose cefoperazone in hemodialysis patients.
    Spyker DA; Richmond JD; Scheld WM; Bolton WK
    Am J Nephrol; 1985; 5(5):355-60. PubMed ID: 4061504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.